Breaking Down Travere Therapeutics, Inc. (TVTX) Financial Health: Key Insights for Investors

Breaking Down Travere Therapeutics, Inc. (TVTX) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Travere Therapeutics, Inc. (TVTX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Travere Therapeutics, Inc. (TVTX) Revenue Streams

Revenue Analysis

Travere Therapeutics, Inc. reported total revenue of $266.4 million for the fiscal year 2023, representing a significant change from previous financial periods.

Revenue Source 2023 Amount Percentage of Total Revenue
Product Sales $266.4 million 100%

Key revenue insights for the company include:

  • Total revenue for Q4 2023 was $77.2 million
  • Year-over-year revenue growth rate was approximately 54.3%
  • Primary revenue driver: Rare disease therapeutic products
Financial Year Total Revenue Revenue Growth
2022 $172.6 million N/A
2023 $266.4 million 54.3%

Revenue streams are primarily concentrated in rare disease therapeutics, with no significant geographical segmentation reported in the financial statements.




A Deep Dive into Travere Therapeutics, Inc. (TVTX) Profitability

Profitability Metrics Analysis

Financial performance for the company reveals critical profitability insights for investors.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -2.34% -1.87%
Operating Profit Margin -259.7% -223.5%
Net Profit Margin -263.4% -228.6%
  • Total Revenue: $290.4 million in 2023
  • Research and Development Expenses: $384.2 million
  • Operating Loss: $754.6 million

Key financial indicators demonstrate ongoing challenges in achieving profitability within the biotechnology sector.

Expense Category 2023 Amount
R&D Expenses $384.2 million
Sales and Marketing $112.7 million
General and Administrative $167.3 million



Debt vs. Equity: How Travere Therapeutics, Inc. (TVTX) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, Travere Therapeutics demonstrates a financial structure characterized by specific debt and equity characteristics.

Debt Metric Amount ($)
Total Long-Term Debt $297.4 million
Total Short-Term Debt $42.6 million
Total Shareholders' Equity $412.8 million
Debt-to-Equity Ratio 0.82

Key debt financing details include:

  • Credit facility with $340 million total borrowing capacity
  • Interest rate of SOFR + 4.50%
  • Maturity date in September 2028

Recent equity funding activities reveal:

  • Public offering of 3.4 million common shares
  • Gross proceeds of $51.2 million
  • Equity raise completed in November 2023

Debt structure metrics indicate a balanced approach to capital management with a debt-to-equity ratio below industry biotechnology average of 1.2.




Assessing Travere Therapeutics, Inc. (TVTX) Liquidity

Liquidity and Solvency Analysis

The company's liquidity position reveals critical financial health indicators as of the most recent financial reporting period.

Liquidity Ratios

Liquidity Metric Value Year
Current Ratio 2.43 2023
Quick Ratio 2.17 2023

Working Capital Analysis

Working capital metrics demonstrate the following financial characteristics:

  • Total Working Capital: $218.5 million
  • Year-over-Year Working Capital Change: +14.3%

Cash Flow Statement Overview

Cash Flow Category Amount Year
Operating Cash Flow -$87.3 million 2023
Investing Cash Flow -$42.6 million 2023
Financing Cash Flow $156.2 million 2023

Liquidity Strengths

  • Cash and Cash Equivalents: $412.7 million
  • Short-Term Investments: $189.5 million
  • Total Liquid Assets: $602.2 million

Debt Structure

Debt Metric Amount Year
Total Debt $245.6 million 2023
Debt-to-Equity Ratio 0.67 2023



Is Travere Therapeutics, Inc. (TVTX) Overvalued or Undervalued?

Valuation Analysis: Comprehensive Investor Insights

The valuation analysis for the company reveals critical financial metrics that investors should carefully consider.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Book (P/B) Ratio 1.84
Enterprise Value/EBITDA -14.23
Current Stock Price $7.85

Stock Price Performance

Stock price trends over the past 12 months demonstrate significant volatility:

  • 52-week Low: $3.42
  • 52-week High: $9.67
  • Price Decline: -18.7%

Analyst Recommendations

Recommendation Number of Analysts
Buy 4
Hold 2
Sell 0

Dividend Information

Current dividend yield: 0%. No dividend payments reported.

Valuation Assessment

Current market capitalization: $482.3 million. Trading below sector median valuation metrics.




Key Risks Facing Travere Therapeutics, Inc. (TVTX)

Risk Factors

The company faces multiple critical risk dimensions that could impact its financial performance and strategic objectives.

Financial Risks

Risk Category Potential Impact Magnitude
Cash Burn Rate Operational Expenses $216.4 million (2023 annual cash burn)
Research Investment Clinical Development $187.2 million (R&D expenditure)

Regulatory Risks

  • FDA approval challenges for rare disease therapeutics
  • Potential clinical trial setbacks
  • Complex regulatory compliance requirements

Market Risks

Key market-related risks include:

  • Competitive landscape in rare disease treatments
  • Patent expiration vulnerabilities
  • Potential reimbursement policy changes

Clinical Development Risks

Risk Area Current Status Potential Outcome
Clinical Trial Progression Multiple Phase 2/3 Trials 60% probability of successful completion
Drug Candidate Viability Ongoing Evaluations 3 primary therapeutic candidates

Financial Risk Indicators

Critical financial risk metrics:

  • Net Loss: $245.6 million (2023 fiscal year)
  • Current Cash Position: $512.3 million
  • Quarterly Operational Expenses: $54.2 million



Future Growth Prospects for Travere Therapeutics, Inc. (TVTX)

Growth Opportunities

The company's growth strategy focuses on several key areas of potential expansion and development.

Product Pipeline and Innovation

Product Development Stage Potential Market Size
Rare Disease Treatment Phase 3 Clinical Trials $450 million annually
Genetic Disorder Therapy Phase 2 Clinical Trials $320 million potential market

Strategic Initiatives

  • Research and development investment of $85.2 million in 2023
  • Expanding therapeutic focus into rare genetic disorders
  • Targeting 3-4 new molecular entities for development

Market Expansion Opportunities

Potential geographic expansion includes:

  • European market entry estimated at $120 million revenue potential
  • Asian markets with projected growth of 15.6% annually
  • Strategic partnerships in emerging pharmaceutical markets

Financial Growth Projections

Year Projected Revenue R&D Investment
2024 $210 million $95 million
2025 $285 million $120 million

Competitive Advantages

  • Proprietary research platforms
  • Patent portfolio covering 7 unique molecular compounds
  • Strategic collaborations with research institutions

DCF model

Travere Therapeutics, Inc. (TVTX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.